-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-515844-22-00
4
2020-09-10
urethral posterior valve
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-517841-16-00
6
2020-07-09
Neurogenic Orthostatic Hypotension
-
2024-511904-18-00
10
2020-07-08
Pancreatic adenocarcinoma (PAC)
-
2024-515276-12-00
5
2020-07-01
Postpartum Hemorrhage
-
2024-511620-13-00
4
2020-06-05
Patient presenting with:
- ectopic ossification secondary to iPPSD2 or
-
2024-512528-13-00
1
2020-05-27
Multiple System Atrophy
-
2024-517185-42-00
3
2020-05-04
Children and teenagers with refractory/relapsing solid tumor
-
2024-510712-75-00
9
2020-02-12
advanced / metastatic
-
2024-514637-37-00
5
2020-02-11
Patients with bone sarcomas other than chordoma, who have no residual
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-516421-30-00
4
2020-02-05
Neonatal hypoxic-ischaemic encephalopathy
-
2024-516266-11-00
5
2020-01-06
yeast intra-abdominal infection, peritonitis
-
2023-508561-33-00
7
2019-12-12
Newly diagnosed, stage III or IV amenable to surgery, HPV negative, sq
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-514362-39-00
4
2019-12-05
Diabetic macular oedema
-
2023-509699-41-00
9
2019-11-22
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
-
2023-507883-38-00
5
2019-11-18
Systemic Juvenile Idiopathic Arthritis
-
2023-507794-17-00
4
2019-11-11
Childhood Epilepsy
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad